Autophagy in Eye Health: Potential and Limits as a Target for Treating Eye Diseases
Links Between Eye Health and Autophagy Dysfunction
Autophagy is the process by which cells break down and recycle components to maintain homeostasis. A review published in Biology Direct synthesizes research on autophagy in the lens, retina, cornea, and trabecular meshwork, and outlines its potential and limitations as a therapeutic target for eye diseases. Autophagy supports cell survival in ocular tissues, but interventions that activate it do not provide protection under every condition.
Under stress, cells use autophagy to break down proteins, lipids, and damaged organelles, obtaining materials needed for metabolism and cell maintenance. Abnormalities in this process are associated with age-related macular degeneration, glaucoma, and cataracts. The paper examines these links by bringing together evidence on basic mechanisms, genetic models, and clinical relevance. Disease-specific mechanisms and therapeutic potential should be interpreted with attention to the subjects and conditions examined in each study.
How Autophagy Maintains Ocular Tissues
The authors reviewed studies examining how autophagy contributes to tissue function and cell survival in the lens, retina, cornea, and trabecular meshwork. In the lens, removal of organelles from differentiating cells contributes to the formation of transparent tissue. In the retina, clearance of damaged components and provision of materials for metabolism are linked to retinal ganglion cell survival. Abnormalities in autophagy and lysosomal function have also been observed in the trabecular meshwork, which handles aqueous humor drainage and intraocular pressure regulation. Immune regulation in the eye was another major topic of the review.
A key distinction concerns “autophagic flux.” This refers to the entire process from the formation of an autophagosome enclosing material for degradation to its fusion with a lysosome and the breakdown of its contents. Observing more autophagosomes alone does not establish that function has improved. They may instead have accumulated because the degradation stage is blocked.
Treatment Strategies Require Context-Specific Modulation
The review examined approaches targeting autophagy pathways, including inhibition of mechanistic target of rapamycin (mTOR), activation of transcription factor EB (TFEB), regulation of non-coding RNAs, and gene editing. Artificial intelligence (AI)-assisted diagnosis was also presented as a topic for consideration, but the provided material contains no specific results assessing diagnostic performance or outcomes from combining it with personalized treatment.
The effects of autophagy modulation varied with the experimental model and the timing and dose of intervention. In glaucoma-related models, studies reported both protection of neurons or axons following autophagy induction and reduced damage following its inhibition. If lysosomes are damaged and degradative flux is blocked, increased autophagosome formation may not indicate restored function.
Evaluation of a therapeutic candidate should consider which tissue and which stage are impaired, as well as how actual degradative function and cell survival change after intervention. Animal models also remain limited in their ability to reproduce human disease adequately. This review alone does not establish prevention of vision loss or effectiveness as a replacement for existing treatments. The research can be found in the article abstract and bibliographic record and the publicly available full text.
Autophagy is a self-digestive process in which cellular components are degraded and recycled to maintain homeostasis and cope with stress. When cells are in a state of stress, autophagy will degrade proteins, lipids and damaged organelles, and convert them into key nutrients and building cornerstones needed to maintain cell homeosis. More and more evidence shows that there is a link between autophagy process damage and the development of a variety of ophthalmic diseases that seriously threaten vision, including age-related macular degeneration, glaucoma and the formation of cataracts. Through a systematic review, we integrate experimental data covering basic biological mechanisms, genetic models and clinical evidence to clarify these pathological associations. With a focus on the mechanisms and regulation of autophagy in various ocular tissues and diseases, we analyzed research on autophagy in the lens, retina, cornea, and trabecular meshwork. Key findings elucidate the specific mechanisms of autophagy in maintaining lens transparency, promoting retinal ganglion cell survival, and regulating ocular immunity, demonstrating its critical role in preserving cellular equilibrium in ocular tissues. Furthermore, we evaluated potential therapeutic strategies targeting autophagic pathways, including mammalian target of rapamycin (mTOR) inhibition, transcription factor EB(TFEB) activation, noncoding RNA regulation, gene editing, and artificial intelligence-assisted diagnostics, which show significant promise for modulating autophagy to treat ocular diseases. The results of this review underscore the importance of autophagy in ocular health and disease.
This review highlights an implication for research design: when evaluating candidates for treating eye diseases, researchers should distinguish increased autophagy from restoration of normal degradative function. For example, preclinical assessment of a glaucoma neuroprotection candidate should examine lysosomal degradative flux, retinal ganglion cell survival, and axonal damage, rather than checking only for increases in autophagosomes or marker proteins. Whether protective and harmful effects vary with the timing and dose of intervention also requires testing. These considerations provide criteria for interpreting a candidate’s action; they neither recommend autophagy-modulating drugs for patients nor establish clinical efficacy.